Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. Blocking αvβ3/galectin-3 binding with GCS-100 selectively.

Slides:

Advertisements

Similar presentations

Cell Growth & Differentiation Vol. 10, , 1999 Inhibition of the Jun Kinase Pathway Blocks DNA Repair, Enhances p53-mediated Apoptosis and Promotes.

Advertisements

A. B. BxPC-3 PANC h h h h h 100 *** * 72 h Cell viability (%) 80 *** *** Cell viability (%) 80 *** *** 60 *** ***

Enhanced DNA damage in IDH1 mutant glioma cells.

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.

Resveratrol modulates DSS-induced neutrophils during colitis.

Fig. 2. Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and MEKi Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and.

ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism by Piro Lito, Martha Solomon, Lian-Sheng Li, Rasmus Hansen, and Neal Rosen.

Cytotoxicity of MSP samples to normal and cancer cell lines.

SKAP55‐deficient mice enhance DC‐based vaccine for prevention of tumors in vivo AWT and SKAP55 KO C57BL/6 mice were s.c. immunized on day −14 and day −7.

DAB2IP expression is selectively lost in luminal B breast cancers and it functions as a tumor suppressor by affecting multiple RAS isoforms. DAB2IP expression.

CCL5 and IL-6 promote RAS-driven lung cancer cell proliferation in 3D culture. CCL5 and IL-6 promote RAS-driven lung cancer cell proliferation in 3D culture.

Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Ectopic expression of wt-DAO, but not the inactive mutant, promotes senescence. Ectopic expression of wt-DAO, but not the inactive mutant, promotes senescence.

Relative growth of transcription factor knockout mutants on different sulfur sources. Relative growth of transcription factor knockout mutants on different.

FBXL19-AS1 acts as a sponge of miR-431-5p in lung cancer (A) The predicted binding sites of FBXL19-AS1 and miR-431-5p, and the mutant sites in mutant-type.

PEDF blockage improved the reduced numbers of circulating CD34+/CD133+/Flk-1+ cells and impaired EPC functions, including migration, adhesion, and tube.

PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded skin. PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded.

Transgenic c-Maf mediates upregulation of type 2 cytokines in NOD CD4, but not CD8, cells. Transgenic c-Maf mediates upregulation of type 2 cytokines in.

Inhibition of lung cancer cell proliferation and viability by CYT387.

PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

PTENP1 sensitizes renal cancer cells to chemotherapy.

A, chemical structures of PRIMA-1 and PRIMA-1Met.

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

ST6GalNAc2 expression enhances tumor cells interaction with the vasculature. ST6GalNAc2 expression enhances tumor cells interaction with the vasculature.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

Ectopic expression of miR-187 in MCF7 cells results in increased migration, invasion, and anchorage-independent colony formation. Ectopic expression of.

Effect of G9a on the expression of GSH synthesis enzymes.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

HNSCC and NSCLC cell lines display differential sensitivities to cixutumumab in the 3D mimic condition. HNSCC and NSCLC cell lines display differential.

Cocultivation of fibroblasts with epithelial cells (EP156T-luc).

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in.

Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,

Combination of miR-520d-3p and EphA2 siRNA treatment shows enhanced EphA2 inhibition and antitumor efficiency in vitro. Combination of miR-520d-3p and.

Combined inhibition of Wee1 and PARP causes persistent radiation-induced DNA damage. Combined inhibition of Wee1 and PARP causes persistent radiation-induced.

Influenza vaccine enhances NK cell function through IFN-α.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

Effect of siltuximab on paclitaxel sensitivity in ovarian cancer drug resistant cells. Effect of siltuximab on paclitaxel sensitivity in ovarian cancer.

FBXL19-AS1 knockdown inhibits proliferation, migration and invasion, and reduces the expression levels of angiogenesis related proteins in lung cancer.

Pdcd4 expression inhibits AP-1 transactivation.

SPARC is required for spontaneous metastasis

A, cell number was assessed 96 hours after exposure to indicated treatment in indicated cell models. A, cell number was assessed 96 hours after exposure.

Effect of bevacizumab on the proliferation of A2780 cells.

αvβ6 functional assays in the β cell line using blocking antibodies.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

ABT-888 sensitizes multiple ovarian cancer cell lines but not normal cells to FdUrd. ABT-888 sensitizes multiple ovarian cancer cell lines but not normal.

CREBBP regulates antigen processing and presentation gene enhancers.

KRAS-addicted lung cancer cells need αvβ3/galectin-3 to maintain low ROS levels. KRAS-addicted lung cancer cells need αvβ3/galectin-3 to maintain low ROS.

GCS-100 selectively kills KRAS-addicted lung tumors.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

MPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. mPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. Cell-to-cell.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

Validation of KMT2D function in MM23, MM2, and MM25 PDXs

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

BRCA1 sequence variants classified as pathogenic do not restore HR

MEK1/2-ERK1/2-p190RHOGAP and INK4a/ARF deficiency drive RHOA activation in NSCLC. A and B, G-LISA assay showing RHOA-GTP levels in H460, A549, and H838.

KRAS co-mutations are associated with distinct therapeutic vulnerabilities. KRAS co-mutations are associated with distinct therapeutic vulnerabilities.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

TRK inhibitor binding to acquired resistance mutations.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Kros of Single grf Knockout Mutants.

Presentation transcript:

Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. A and B, A cell-free binding assay shows direct binding between integrin αvβ3 and galectin-3, and its competitive inhibition by lactose. C, A galectin-3 inhibitor, GCS-100, disrupts αvβ3/galectin-3 binding in the cell-free assay. D, Flow cytometer analysis for cell surface galectin-3 expression. E and F, The effect of GCS-100 on 3-D viability of KRAS-mutant lung cancer cell lines and PDX models is enhanced by αvβ3 expression. G, Embryonic fibroblasts from genetically engineered mice [wild-type, KrasG12D, Lgals3 knockout (KO), or the combination] were compared for sensitivity to GCS-100. All data represent mean ± SD from at least three independent experiments. Statistical significance was determined by the Student t test. *, P < 0.05; **, P < 0.01. Laetitia Seguin et al. Cancer Discov 2017;7:1464-1479 ©2017 by American Association for Cancer Research